Literature DB >> 8288702

Production of bioactive and immunoreactive interleukin-6 (IL-6) and expression of IL-6 messenger ribonucleic acid by human pituitary adenomas.

T H Jones1, M Daniels, R A James, S K Justice, R McCorkle, A Price, P Kendall-Taylor, A P Weetman.   

Abstract

Preliminary studies have demonstrated that some pituitary adenomas secrete immunoreactive interleukin-6 (irIL-6) when cultured in vitro. We have extended these studies by investigating 100 pituitary adenomas of different types measuring immunoreactive and bioactive IL-6. Tumors were cultured either as explants without fetal calf serum or as dispersed cells with 10% total calf serum. Fifty-three of the 100 (53%) pituitary cultures were found to release irIL-6 and in 44 adenomas examined, 32 (72.7%) secreted bioactive IL-6. In 61 explant cultures, 30 adenomas released IL-6, indicating autonomous secretion. The amount of IL-6 released by adenomas in cell culture was generally higher, although the incidence was similar to explant cultures. IrIL-6 was released by 7 of 14 prolactinomas, 15 of 27 somatotrophinomas, 5 of 7 corticotrophinomas (including 2 Nelson's adenomas), 1 of 1 thyrotrophinomas, 2 of 2 gonadotrophinomas, and 23 of 49 clinically non-functioning adenomas. Periadenomatous tissue removed from a patient with a corticotrophinoma was found to secrete IL-6 but in much lower concentration than from the adenoma tissue. Tumor necrosis factor-alpha and -gamma-interferon were not detected in the conditioned media. Four IL-6-secreting adenomas were examined by in situ hybridization for IL-6 messenger RNA, and three of these were positive with fluorescence present throughout the tissue examined. We have provided evidence that over half of pituitary adenomas secrete IL-6 which is bioactive and that IL-6 is synthesized within the tumor by the adenoma cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288702     DOI: 10.1210/jcem.78.1.8288702

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Characterization of Interleukin-2 (IL-2) receptor expression and action of IL-2 and IL-6 on normal anterior pituitary cell growth.

Authors:  E Arzt; J Sauer; R Buric; J Stalla; U Renner; G K Stalla
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

2.  Immunohistochemical localization of interleukin-6 in peripheral human endocrine glands.

Authors:  George Kontogeorgos; Irene Messini; Efi Kyrodimou; Linda Giannikaki; Emmanuel Zois; George Koukoulis; Stylianos Tsagarakis
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.633

3.  Interleukin-6 stimulates cell proliferation of rat pituitary clonal cell lines in vitro.

Authors:  T Sawada; K Koike; Y Kanda; H Ikegami; H Jikihara; T Maeda; Y Osako; K Hirota; A Miyake
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

4.  Pituitary adenoma growth: a model for cellular senescence and cytokine action.

Authors:  Eduardo Arzt; Vera Chesnokova; Günter K Stalla; Shlomo Melmed
Journal:  Cell Cycle       Date:  2009-03-12       Impact factor: 4.534

5.  Percoll Density Gradient-Enriched Populations of Rat Pituitary Cells: Interleukin 6 Secretion, Proliferative Activity, and Nitric Oxide Synthase Expression.

Authors:  Xiang Qian; Long Jin; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

Review 6.  Leptin and leptin receptor in anterior pituitary function.

Authors:  R V Lloyd; L Jin; I Tsumanuma; S Vidal; K Kovacs; E Horvath; B W Scheithauer; M E Couce; B Burguera
Journal:  Pituitary       Date:  2001 Jan-Apr       Impact factor: 4.107

7.  Pathogenesis analysis of pituitary adenoma based on gene expression profiling.

Authors:  Weimin Wang; Zhiming Xu; Li Fu; Wei Liu; Xingang Li
Journal:  Oncol Lett       Date:  2014-10-13       Impact factor: 2.967

8.  Autocrine IL-6 mediates pituitary tumor senescence.

Authors:  Melanie Sapochnik; Mariana R Haedo; Mariana Fuertes; Pablo Ajler; Guillermo Carrizo; Andrés Cervio; Gustavo Sevlever; Günter K Stalla; Eduardo Arzt
Journal:  Oncotarget       Date:  2017-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.